VX12-809-105: A Phase 3, Rollover Study to Evaluate

Project: Research project

Project Details

Description

VX12-809-105: A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mut
StatusFinished
Effective start/end date12/6/1312/6/16

Funding

  • Vertex Pharmaceuticals Incorporated

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.